1st Quarter - Report

FOLEY HOAG LLP for GILEAD SCIENCES INC

Firm
Client
Income
$14,500
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.

LobbyistCovered position, as disclosed
PAUL KIM —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 524 (115th), S. 3056 (115th), S. 1287 (115th), H.R. 6 (115th)

Medicare/Medicaid MMM

Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV testing, screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.

LobbyistCovered position, as disclosed
PAUL KIM —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (115th)

Pharmacy PHA

Coverage of pharmaceuticals, cost-sharing, and other access issues, H.R. 21st Century Cures Act; Implementation of Pub. L. No. 114-1448, the ACA; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B. S. 3056: CREATES Act of 2016.

LobbyistCovered position, as disclosed
PAUL KIM —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 21 (115th), S. 3056 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.